Franco Roviello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9154932/publications.pdf

Version: 2024-02-01

123 papers 4,062 citations

28 h-index 59 g-index

123 all docs

123
docs citations

123 times ranked 5298 citing authors

#	Article	lF	CITATIONS
1	Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM). European Radiology, 2022, 32, 938-949.	4.5	4
2	Signet ring cell percentage in poorly cohesive gastric cancer patients: A potential novel predictor of survival. European Journal of Surgical Oncology, 2022, 48, 561-569.	1.0	18
3	Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 681.	2.6	2
4	Antimicrobial Prophylaxis Reduces the Rate of Surgical Site Infection in Upper Gastrointestinal Surgery: A Systematic Review. Antibiotics, 2022, 11, 230.	3.7	11
5	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	2.8	27
6	The utility of intraoperative PTH dosage in primary hyperparathyroidism based on preoperative diagnosis and surgical choice. Minerva Surgery, 2022, , .	0.6	0
7	Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine. Genes, 2022, 13, 460.	2.4	7
8	Methylene Blue Near-Infrared Fluorescence Imaging in Breast Cancer Sentinel Node Biopsy. Cancers, 2022, 14, 1817.	3.7	5
9	Handgrip strength predicts length of hospital stay in an abdominal surgical setting: the role of frailty beyond age. Aging Clinical and Experimental Research, 2022, , 1 .	2.9	16
10	Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. Journal of Medical Genetics, 2021, 58, 1-11.	3.2	20
11	Surgical management of oncologic patient during and after the COVID-19 outbreak: practical recommendations from the Italian society of Surgical Oncology. Updates in Surgery, 2021, 73, 321-329.	2.0	19
12	Robotic-assisted gastrectomy for gastric cancer: single Western center results. Updates in Surgery, 2021, 73, 865-872.	2.0	7
13	Upper GI training of young surgeons: a reality full of hurdles. An international survey. Updates in Surgery, 2021, 73, 627-637.	2.0	2
14	Cancer networks as a response to COVID pandemic: A framework from the Italian Society of Surgical Oncology. Journal of Surgical Oncology, 2021, 123, 1201-1203.	1.7	1
15	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. Gastric Cancer, 2021, 24, 765-779.	5.3	12
16	Maintenance in gastric cancer: New life for an old issue?. Critical Reviews in Oncology/Hematology, 2021, 160, 103307.	4.4	4
17	ASO Author Reflections: Gastric Cancer with Synchronous Peritoneal Disease—A Clinically Meaningful Survival After CRS and HIPEC in Selected Patients from Italian Peritoneal Surface Malignancies Oncoteam Network. Annals of Surgical Oncology, 2021, 28, 9071-9072.	1.5	1
18	Robotic versus laparoscopic gastrectomy for gastric cancer: an umbrella review of systematic reviews and meta-analyses. Updates in Surgery, 2021, 73, 1673-1689.	2.0	17

#	Article	IF	CITATIONS
19	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of †Italian Peritoneal Surface Malignancies Oncoteam—S.I.C.O.'. Annals of Surgical Oncology, 2021, 28, 9060-9070.	1.5	24
20	A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer. Surgical Oncology, 2021, 37, 101523.	1.6	6
21	Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer—a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quantitative Imaging in Medicine and Surgery, 2021, 11, 2376-2387.	2.0	26
22	2-Dimensional ultra-high performance liquid chromatography and DMT-MM derivatization paired with tandem mass spectrometry for comprehensive serum N-glycome characterization. Analytica Chimica Acta, 2021, 1179, 338840.	5.4	1
23	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	12.3	69
24	The effect of learning curve on perioperative outcomes of robotic gastrectomy in two western highâ€volume centers. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2212.	2.3	4
25	Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study. Pleura and Peritoneum, 2021, 6, 21-30.	1.2	2
26	Looking for a strategy in treating peritoneal gastric cancer carcinomatosis: an Italian multicenter Gastric Cancer Research group's analysis. World Journal of Surgical Oncology, 2021, 19, 334.	1.9	3
27	Complete Mesogastric Excisions Involving Anatomically Based Concepts and Embryological-Based Surgeries: Current Knowledge and Future Challenges. Current Oncology, 2021, 28, 4929-4937.	2.2	2
28	Short-termÂoutcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of colo-rectal carcinomatosis: a multicentric study. Updates in Surgery, 2020, 72, 163-170.	2.0	8
29	Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel,) Tj ETQq1 1 0.784314 non-metastatic gastric cancer. Surgical Oncology, 2020, 32, 2-7.	4 rgBT /O\ 1.6	
30	Methylene Blueâ€"Current Knowledge, Fluorescent Properties, and Its Future Use. Journal of Clinical Medicine, 2020, 9, 3538.	2.4	64
31	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. Critical Reviews in Oncology/Hematology, 2020, 152, 102987.	4.4	6
32	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link with Novel Immunotherapy. Journal of Clinical Medicine, 2020, 9, 1427.	2.4	55
33	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Translational Oncology, 2020, 13, 100795.	3.7	26
34	Clinical evaluation of the Mannheim Prognostic Index in post-operative peritonitis: a prospective cohort study. Updates in Surgery, 2020, 72, 1159-1166.	2.0	9
35	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers, 2020, 12, 1598.	3.7	37
36	Robotic versus laparoscopic gastrectomy for gastric cancer: protocol for umbrella review of systematic reviews and meta-analyses. BMJ Open, 2020, 10, e033634.	1.9	5

#	Article	IF	Citations
37	New technologies in breast cancer sentinel lymph node biopsy; from the current gold standard to artificial intelligence. Surgical Oncology, 2020, 34, 324-335.	1.6	25
38	Perioperative chemotherapy for gastric cancer in FLOT4. Lancet, The, 2020, 395, e3.	13.7	3
39	Cancer care under the outbreak of COVID-19: A perspective from Italian tertiary referral center for surgical oncology. European Journal of Surgical Oncology, 2020, 46, 1184-1185.	1.0	9
40	Germline mutations of the E-cadherin gene (CDH1) in early onset gastric cancer. Seminars in Oncology, 2020, 47, 125-126.	2.2	1
41	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers, 2020, 12, 2790.	3.7	15
42	International consensus on a complications list after gastrectomy for cancer. Gastric Cancer, 2019, 22, 172-189.	5.3	78
43	Smartphone application supplements laparoscopic training through simulation by reducing the need for feedback from expert tutors. Surgery Open Science, 2019, 1, 100-104.	1.2	1
44	A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. EBioMedicine, 2019, 44, 322-333.	6.1	52
45	Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer, 2019, 22, 1285-1293.	5.3	46
46	Oâ€glycan truncation enhances cancerâ€related functions of <scp>CD</scp> 44 in gastric cancer. FEBS Letters, 2019, 593, 1675-1689.	2.8	36
47	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. European Journal of Cancer, 2019, 112, 1-8.	2.8	23
48	Comparison between 7th and 8th edition of AJCC TNM staging system for gastric cancer: old problems and new perspectives. Translational Gastroenterology and Hepatology, 2019, 4, 22-22.	3.0	41
49	From digital world to real life: a robotic approach to the esophagogastric junction with a 3D printed model. BMC Surgery, 2019, 19, 153.	1.3	8
50	The Cholegas trial: long-term results of prophylactic cholecystectomy during gastrectomy for cancer—a randomized-controlled trial. Gastric Cancer, 2019, 22, 632-639.	5.3	23
51	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. Pathology and Oncology Research, 2019, 25, 333-340.	1.9	29
52	An aggressive early gastric cancer: Kodama's PenA type. European Journal of Surgical Oncology, 2018, 44, 1186-1190.	1.0	5
53	Sample handling of gastric tissue and O-glycan alterations in paired gastric cancer and non-tumorigenic tissues. Scientific Reports, 2018, 8, 242.	3.3	16
54	Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist, 2018, 23, 852-858.	3.7	10

#	Article	IF	CITATIONS
55	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. Neoplasia, 2018, 20, 443-455.	5.3	17
56	Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. European Journal of Surgical Oncology, 2018, 44, 626-631.	1.0	16
57	Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype. Pathology and Oncology Research, 2018, 24, 393-400.	1.9	27
58	Oncologic Effectiveness and Safety of Bursectomy in Patients with Advanced Gastric Cancer: A Systematic Review and Updated Meta-Analysis. Journal of Investigative Surgery, 2018, 31, 529-538.	1.3	9
59	The Thomsen-Friedenreich Antigen: A Highly Sensitive and Specific Predictor of Microsatellite Instability in Gastric Cancer. Journal of Clinical Medicine, 2018, 7, 256.	2.4	14
60	Clinical impact of molecular classifications in gastric cancer. Updates in Surgery, 2018, 70, 225-232.	2.0	13
61	Mining the acidic serum proteome utilizing off-gel isoelectric focusing and label free quantitative liquid chromatography mass spectrometry. Journal of Chromatography A, 2018, 1566, 32-43.	3.7	4
62	Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. Journal of Medical Genetics, 2018, 55, 431-441.	3.2	68
63	Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study. Gastroenterology Research and Practice, 2018, 2018, 1-10.	1.5	21
64	Familial aggregation of gastric cancer with microsatellite instability*. Acta Chirurgica Belgica, 2018, 118, 287-293.	0.4	4
65	Hereditary diffuse gastric cancer: how to look for and how to manage it. Updates in Surgery, 2018, 70, 161-166.	2.0	6
66	PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene. Advances in Clinical and Experimental Medicine, 2018, 27, 963-969.	1.4	19
67	Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer, 2017, 20, 217-225.	5.3	357
68	The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer, 2017, 20, 20-30.	5.3	144
69	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 2017, 20, 904-912.	5.3	33
70	Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. Cancer Investigation, 2017, 35, 187-194.	1.3	11
71	Incidence and Prognostic Value of Metastases to "Posterior―and Para-aortic Lymph Nodes in Resectable Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 2273-2280.	1.5	15
72	Trans-pericardal Color Doppler Ultra Sound to Assess Blood Flow in the Visceral Branches during Type A Dissection Procedures Complicated with Mesenteric Malperfusion. Annals of Vascular Surgery, 2017, 44, 420.e1-420.e5.	0.9	3

#	Article	IF	CITATIONS
73	Epitope mapping of a new anti-Tn antibody detecting gastric cancer cells. Glycobiology, 2017, 27, 635-645.	2.5	15
74	Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study. Clinical Colorectal Cancer, 2017, 16, 334-342.	2.3	48
75	Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification. Cancer Investigation, 2017, 35, 325-332.	1.3	4
76	The pattern of lymph node metastases in microsatellite unstable gastric cancer. European Journal of Surgical Oncology, 2017, 43, 2341-2348.	1.0	19
77	Complications after gastrectomy for cancer: Italian perspective. Updates in Surgery, 2017, 69, 285-288.	2.0	10
78	Molecular key to understand the gastric cancer biology in elderly patientsâ€"The role of microsatellite instability. Journal of Surgical Oncology, 2017, 115, 344-350.	1.7	24
79	1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer. Tumori, 2017, 103, 525-536.	1.1	11
80	Lymphadenectomy: state of the art. Translational Gastroenterology and Hepatology, 2017, 2, 3-3.	3.0	5
81	Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?. Current Issues in Pharmacy and Medical Sciences, 2017, 30, 203-206.	0.4	0
82	Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability?. Translational Gastroenterology and Hepatology, 2016, 1, 11-11.	3.0	7
83	Surgery for liver metastasis from gastric cancer. Translational Gastroenterology and Hepatology, 2016, 1, 68-68.	3.0	2
84	Gastric cancer: Current status of lymph node dissection. World Journal of Gastroenterology, 2016, 22, 2875.	3.3	124
85	High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1817-1824.	2.5	6
86	Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 102, 82-88.	4.4	29
87	Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives. Surgical Oncology, 2016, 25, 355-363.	1.6	12
88	Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas. Tumor Biology, 2016, 37, 1959-1966.	1.8	14
89	Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Letters, 2016, 372, 187-191.	7.2	126
90	Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-cardia Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 943-950.	1.5	102

#	Article	IF	CITATIONS
91	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumor Biology, 2016, 37, 127-140.	1.8	9
92	Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer, 2016, 19, 31-41.	5.3	48
93	Laparoscopy Versus Robotic Surgery for Colorectal Cancer. Surgical Innovation, 2016, 23, 374-380.	0.9	19
94	Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence. International Journal of Hyperthermia, 2016, 32, 173-179.	2.5	11
95	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer, 2016, 19, 15-20.	5.3	51
96	Assessing the feasibility of full robotic interaortocaval nodal dissection for locally advanced gastric cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2015, 11, 218-222.	2.3	5
97	Clinical and Oncological Value of Preoperative BMI in Gastric Cancer Patients: A Single Center Experience. Gastroenterology Research and Practice, 2015, 2015, 1-8.	1.5	13
98	Multimodal treatment of gastric cancer in the west: Where are we going?. World Journal of Gastroenterology, 2015, 21, 7954.	3.3	59
99	Intestinal Stenosis of Garré: An Old Problem Revisited. Visceral Medicine, 2015, 31, 209-211.	1.3	1
100	Gastric stump carcinoma after distal subtotal gastrectomy for early gastric cancer: experience of 541 patients with long-term follow-up. American Journal of Surgery, 2015, 209, 1063-1068.	1.8	39
101	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
102	c-Met targeting in advanced gastric cancer: An open challenge. Cancer Letters, 2015, 365, 30-36.	7.2	67
103	Robotic single docking total colectomy for ulcerative colitis: First experience with a novel technique. International Journal of Surgery, 2015, 21, 63-67.	2.7	17
104	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	7.1	540
105	Hyperthermic intraperitoneal chemotherapy for the treatment of ovarian cancer: A brief overview of recent results. Critical Reviews in Oncology/Hematology, 2015, 95, 297-305.	4.4	12
106	External Validation of a Score Predictive of Recurrence after Radical Surgery for Non-Cardia Gastric Cancer: Results of a Follow-Up Study. Journal of the American College of Surgeons, 2015, 221, 280-290.	0.5	24
107	Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status. Journal of Geriatric Oncology, 2015, 6, 380-386.	1.0	7
108	Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer. Future Oncology, 2015, 11, 2563-2574.	2.4	1

#	Article	IF	CITATIONS
109	Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: preliminary analysis of a multicentre study. Anticancer Research, 2014, 34, 5689-93.	1.1	28
110	Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention Journal of Clinical Oncology, 2013, 31, e22037-e22037.	1.6	0
111	Gastric cancer with synchronous hepatic metastases: A multicentric Italian survey Journal of Clinical Oncology, 2013, 31, e15148-e15148.	1.6	1
112	Is Circulating D-Dimer Level a Better Prognostic Indicator than Cea in Resectable Colorectal Cancer? Our Experience on 199 Cases. International Journal of Biological Markers, 2010, 25, 171-176.	1.8	10
113	Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. Journal of Surgical Oncology, 2010, 102, 663-670.	1.7	67
114	A Rare Case of Primary Small Bowel Adenocarcinoma with Intussusception. Tumori, 2010, 96, 355-357.	1.1	2
115	In Reply: Issues of Outcome in Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 2379-2379.	1.5	1
116	Primary Osteosarcoma of the Kidney with Retroperitoneal Hemorrhage. Case Report and Review of the Literature. Tumori, 2007, 93, 213-216.	1.1	14
117	Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemoperfusion (IHCP): Postoperative Outcome and Risk Factors for Morbidity. World Journal of Surgery, 2006, 30, 2033-2040.	1.6	74
118	Small bowel metastases from renal cell carcinoma: a rare cause of intestinal intussusception. Journal of Nephrology, 2006, 19, 234-8.	2.0	14
119	Iron deficiency anemia after subtotal gastrectomy for gastric cancer. Hepato-Gastroenterology, 2004, 51, 1510-4.	0.5	3
120	Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: A longitudinal multicenter study. Annals of Surgical Oncology, 2002, 9, 894-900.	1.5	89
121	p53 Accumulation Is a Prognostic Factor in Intestinal-Type Gastric Carcinoma but Not in the Diffuse Type. Annals of Surgical Oncology, 1999, 6, 739-745.	1.5	24
122	Complications After Surgery for Gastric Cancer in Patients Aged 80 Years and Over. Japanese Journal of Clinical Oncology, 1998, 28, 116-122.	1.3	30
123	Cell proliferation, cell death and angiogenesis in early and advanced gastric cancer of intestinal type. , 1997, 74, 637-641.		12